Circulating levels of matrix proteases and their inhibitors in pregnant women with and without a history of recurrent pregnancy loss

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Anumba, Dilly O C ^a   El Gelany, Saad ^a   Elliott, Sarah L ^a   Li, Tin C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; RELAXIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; ENZYME BLOOD LEVEL; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; PREDICTION; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; RECEIVER OPERATING CHARACTERISTIC; RECURRENT ABORTION; RELIABILITY; SPONTANEOUS ABORTION; BLOOD; CASE CONTROL STUDY; EMBRYO DEATH; FETUS BLOOD; GESTATIONAL AGE; METABOLISM; REPRODUCTIVE HISTORY;

ABORTION, HABITUAL; ADULT; CASE-CONTROL STUDIES; EMBRYO LOSS; FEMALE; FETAL BLOOD; GESTATIONAL AGE; HUMANS; MATRIX METALLOPROTEINASES; PREGNANCY; REPRODUCTIVE HISTORY; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 77953501697     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-52     Document Type: Article

References (42)

1. Mtiraoui N, Borgi L, Gris JC, Almawi WY, Mahjoub T. Factor V Leiden, prothrombin G20210A and antibodies against phospholipids in recurrent spontaneous abortion. J Thromb Haemost 2004, 2:1482-1484. 10.1111/j.1538-7836.2004.00856.x, 15304067.
2. Palomba S, Falbo A, Orio F, Russo T, Tolino A, Zullo F. Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. Fertil Steril 2006, 85:e3-5. 1511, 10.1016/j.fertnstert.2005.09.063, 16647382.
3. Craig LB, Ke RW, Kutteh WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002, 78:487-490. 10.1016/S0015-0282(02)03247-8, 12215322.
4. Emmer PM, Steegers EA, Kerstens HM, Bulten J, Nelen WL, Boer K, Joosten I. Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in pathological pregnancies. Hum Reprod 2002, 17:1072-1080. 10.1093/humrep/17.4.1072, 11925408.
5. Prakash A, Laird S, Tuckerman E, Li TC, Ledger WL. Inhibin A and activin A may be used to predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2005, 83:1758-1763. 10.1016/j.fertnstert.2004.11.072, 15950648.
6. Salim R, Miel J, Savvas M, Lee C, Jurkovic D. A comparative study of glycodelin concentrations in uterine flushings in women with subseptate uteri, history of unexplained recurrent miscarriage and healthy controls. Eur J Obstet Gynecol Reprod Biol 2007, 133:76-80. 10.1016/j.ejogrb.2006.09.005, 17049713.
7. Carp H, Dardik R, Lubetsky A, Salomon O, Eskaraev R, Rosenthal E, Inbal A. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: A case-controlled study. Hum Reprod 2004, 19:191-195. 10.1093/humrep/deg512, 14688181.
8. Laird SM, Quinton ND, Anstie B, Li TC, Blakemore AI. Leptin and leptin-binding activity in women with recurrent miscarriage: Correlation with pregnancy outcome. Hum Reprod 2001, 16:2008-2013. 10.1093/humrep/16.9.2008, 11527914.
9. Anumba DO, El Gelany S, Elliott SL, Li TC. Serum relaxin levels are reduced in pregnant women with a history of recurrent miscarriage, and correlate with maternal uterine artery doppler indices in first trimester. Eur J Obstet Gynecol Reprod Biol 2009, 147:41-45. 10.1016/j.ejogrb.2009.07.008, 19695764.
10. Johnson MR, Jauniaux E, Jurkovic D, Sannino P, Campbell S, Nicolaides KH. Relaxin concentrations in exoembryonic fluids during the first trimester. Hum Reprod 1994, 9:1561-1562.
11. Piccinni MP, Maggi E, Romagnani S. Role of hormone-controlled t-cell cytokines in the maintenance of pregnancy. Biochem Soc Trans 2000, 28:212-215.
12. Jivraj S, Anstie B, Cheong YC, Fairlie FM, Laird SM, Li TC. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: A cohort study. Hum Reprod 2001, 16:102-106. 10.1093/humrep/16.1.102, 11139545.
13. Ho TY, Bagnell CA. Relaxin induces matrix metalloproteinase-9 through activation of nuclear factor kappa B in human THP-1 cells. Ann N Y Acad Sci 2005, 1041:314-316. 10.1196/annals.1282.049, 15956726.
14. Jeyabalan A, Kerchner LJ, Fisher MC, McGuane JT, Doty KD, Conrad KP. Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol 2006, 100:1955-1963. 10.1152/japplphysiol.01330.2005, 16484357.
15. Lenhart JA, Ryan PL, Ohleth KM, Palmer SS, Bagnell CA. Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and -2 during uterine and cervical growth and remodeling in the pig. Endocrinology 2002, 143:91-98. 10.1210/en.143.1.91, 11751597.
16. Goldsmith LT, Weiss G. Relaxin regulates endometrial structure and function in the rhesus monkey. Ann N Y Acad Sci 2005, 1041:110-117. 10.1196/annals.1282.015, 15956693.
17. Vagnoni KE, Zheng J, Magness RR. Matrix metalloproteinases-2 and -9, and tissue inhibitor of metalloproteinases-1 of the sheep placenta during the last third of gestation. Placenta 1998, 19:447-455. 10.1016/S0143-4004(98)91037-2, 9778117.
18. Xu P, Wang Y, Piao Y, Bai S, Xiao Z, Jia Y, Luo S, Zhuang L. Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol Reprod 2001, 65:240-246. 10.1095/biolreprod65.1.240, 11420245.
19. Hollis B, Mavrides E, Campbell S, Tekay A, Thilaganathan B. Reproducibility and repeatability of transabdominal uterine artery doppler velocimetry between 10 and 14 weeks of gestation. Ultrasound Obstet Gynecol 2001, 18:593-597. 10.1046/j.0960-7692.2001.00544.x, 11844196.
20. Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol 1995, 6:168-174. 10.1046/j.1469-0705.1995.06030168.x, 8521065.
21. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: Metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6. 10.1126/scisignal.127re6, 2493614, 18612141.
22. Weise S, Kralisch S, Sommer G, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Tissue inhibitor of metalloproteinase-1 mRNA production and protein secretion are induced by interleukin-1 beta in 3T3-L1 adipocytes. J Endocrinol 2008, 198:169-174. 10.1677/JOE-07-0631, 18577571.
23. Stetler-Stevenson WG, Seo DW. TIMP-2: An endogenous inhibitor of angiogenesis. Trends Mol Med 2005, 11:97-103. 10.1016/j.molmed.2005.01.007, 15760767.
24. Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001, 276:3203-3214. 10.1074/jbc.M008157200, 11042184.
25. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 2003, 114:171-180. 10.1016/S0092-8674(03)00551-8, 12887919.
26. Stojanovic N, Lewandowski K, Salata I, Bienkiewicz M, Tuck S, Prelevic G, Press M. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls. Gynecol Endocrinol 2009, 12:1-7.
27. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002, 3:1177-1189. 10.1517/14656566.3.11.1557, 12150695.
28. Diejomaoh M, Jirous J, Al-Azemi M, Gupta M, Al-Jaber M, Farhat R, Mohd A. Insulin resistance in women with recurrent spontaneous miscarriage of unknown aetiology. Med Princ Pract 2007, 16:114-118. 10.1159/000098363, 17303946.
29. Carrington B, Sacks G, Regan L. Recurrent miscarriage: Pathophysiology and outcome. Curr Opin Obstet Gynecol 2005, 17:591-597. 10.1097/01.gco.0000194112.86051.26, 16258340.
30. Boden G, Song W, Kresge K, Mozzoli M, Cheung P. Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. Am J Physiol Endocrinol Metab 2008, 295:E692-697. 10.1152/ajpendo.90370.2008, 2536734, 18664596.
31. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993, 157:351-358. 10.1002/jcp.1041570219, 7693724.
32. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 1995, 6:255-263. 10.1016/0955-2235(95)00017-8, 8817668.
33. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Gelatinase matrix metalloproteinase (MMP)-2 and MMP-9 of the umbilical cord blood in preeclampsia. Clin Chem Lab Med 2008, 46:517-522. 10.1515/CCLM.2008.083, 18298353.
34. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 2005, 24:103-115. 10.1081/PRG-200059836, 16036395.
35. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008, 41:875-880. 10.1016/j.clinbiochem.2008.04.015, 18477480.
36. Makrakis E, Grigoriou O, Kouskouni E, Vitoratos N, Salamalekis E, Chatzoudi E, Creatsas G. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in plasma/serum and urine of women during term and threatened preterm labor: A clinical approach. J Matern Fetal Neonatal Med 2003, 14:170-176.
37. Lu D, Wang ZX, Wang XL, Gu XW, Wang YX, Fu D. [clinical significance of matrix metalloproteinase-9/tissue inhibitors of matrix metalloproteinase -1 imbalance in maternal serum, amniotic fluid, umbilical cord serum in patients with premature rupture of the membranes]. Zhonghua Fu Chan Ke Za Zhi 2006, 41:20-24.
38. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999, 878:212-227. 10.1111/j.1749-6632.1999.tb07687.x, 10415733.
39. Oner C, Schatz F, Kizilay G, Murk W, Buchwalder LF, Kayisli UA, Arici A, Lockwood CJ. Progestin-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells: Implications for treatment of chorioamnionitis-induced preterm delivery. J Clin Endocrinol Metab 2008, 93:252-259. 10.1210/jc.2007-1538, 2190749, 17940116.
40. Park KH, Chaiworapongsa T, Kim YM, Espinoza J, Yoshimatsu J, Edwin S, Gomez R, Yoon BH, Romero R. Matrix metalloproteinase 3 in parturition, premature rupture of the membranes, and microbial invasion of the amniotic cavity. J Perinat Med 2003, 31:12-22. 10.1515/JPM.2003.002, 12661139.
41. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman I, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658. 151901, 12618519.
42. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J, Grove BH. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod 1999, 14:800-806. 10.1093/humrep/14.3.800, 10221717.